Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2a Study of STM-416 Administered Intraoperatively to Patients Undergoing Transurethral Resection of Bladder Tumor (TURBT) for Recurrent High-Grade Papillary Bladder Cancer

NCT05710848 is registered in ClinicalTrials.gov with SURGE Therapeutics as lead sponsor.

NCT NCT05710848
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05710848 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2a Study of STM-416 Administered Intraoperatively to Patients Undergoing Transurethral Resection of Bladder Tumor (TURBT) for Recurrent High-Grade Papillary Bladder Cancer
Lead sponsor
SURGE Therapeutics
Phase
Phase 1/2
Overall status
Recruiting
Start date
July 11, 2023
Completion date
August 31, 2026
Enrollment
75 (estimated)
Sites
20

Conditions

As the registry lists them; a condition with its own page is linked.

non-muscle-invasive bladder cancer